Hemodialysis, membrane-related neutrophil dysfunctions, and pentoxifylline--a pilot study.
Hemodialysis treatment is associated with activation of neutrophil granulocytes. Pentoxifylline has been shown to inhibit neutrophil activation in vitro and in vivo. We investigated the effect of pentoxifylline on leukocyte and platelet counts and on plasma levels of extracellularly released neutrophil elastase and lactoferrin during a four-hour hemodialysis treatment. Eight patients received 400 mg of pentoxifylline or placebo orally twice a day over 14 days and an additional dose of 400 mg of pentoxifylline intravenously during hemodialysis. Each subject served as his own control in a randomized, double-blind, cross-over study. Combined oral and intravenous treatment with pentoxifylline prevented neither leukopenia nor neutrophil degranulation during the time interval studied. Elastase plasma levels paralleled the drop in leucocyte counts and thereafter increased similarly in both groups. Lactoferrin plasma levels exhibited less increase in the treated group; however, this effect was not statistically significant. This may be due to the small number of cases studied and to difficulties in reaching effective plasma levels without side effects.
Spannagl
M
M
Medizinische Klinik Innenstadt, Ludwig-Maximilians-Universität München.
Schiffl
H
H
Hoffmann
H
H
Jochum
M
M
D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007781:Lactoferrin / Q000097:blood; D007958:Leukocyte Count / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects* / Q000201:enzymology / Q000276:immunology; D010196:Pancreatic Elastase / Q000097:blood; D010431:Pentoxifylline / Q000008:administration & dosage / Q000494:pharmacology*; D010865:Pilot Projects; D010976:Platelet Count / Q000187:drug effects; D006435:Renal Dialysis
D007781:Lactoferrin; D010196:Pancreatic Elastase; D010431:Pentoxifylline